Spain is set to introduce a new medical cannabis law as early as next month after the government announced that the Spanish Agency for Medicines and Health Products (AEMPS) is working on the draft. Patients who will be able to access cannabis will be those with multiple sclerosis, epilepsy, chemotherapy-derived nausea and vomiting, endometriosis, cancer pain, and chronic non-oncology pain.
In Spain, the Ministry of Health is drafting a law regulating medical cannabis in the country. It is expected that the new law will be presented next month.
To follow more more cannabis stories from Spain and around the world, download our free cannabis news app.
Health Agency Working On Draft
The Spanish government announced that the Spanish Agency for Medicines and Health Products (AEMPS) is working on the draft, after a deputy from the Ciudadanos political party asked a parliamentary question.
“AEMPS is preparing a roadmap for the appropriate regulatory framework and the viability of these recommendations,” the Spanish government responded after being asked about regulatory advances and the roadmap for the medical use of the plant.
To this, it added that this law will “guarantee the quality of these products (extracts or standardized cannabis preparations) so that their use contributes to the health of patients who may need them and to the protection of public health.”
Medical Cannabis Available in Spain by Year’s End?
The AEMPS seeks to meet the deadline set by the Congress of Deputies’ Subcommittee on Medical Cannabis, which recommended last June that medical cannabis be available in pharmacies in Spain by the end of 2022.
Whether it can achieve this target date is still unknown, however, it is looking extremely unlikely given there’s not much more than a month left to the year.
The Regulation of Medical Cannabis in Spain Is Approaching
What other suggestions did the congressional subcommittee make regarding medical cannabis?
The text states that “the dispensing of magistral formulas with extracts or standardized preparations of cannabis should be carried out by the network of pharmacies of the health system, giving priority to hospital pharmacies and exploring the alternative of community pharmacies that can meet the requirements.”
Patient Access to Cannabis in Spain
Patients in Spain who will be able to access cannabis will be those suffering from multiple sclerosis, certain forms of epilepsy, chemotherapy-derived nausea and vomiting, endometriosis, cancer pain, and chronic non-oncology pain (including neuropathic pain). There is also the possibility of expanding to other therapeutic indications when studies provide consistent evidence.
In particular, it remains to be defined whether cannabis flowers for vaporization will be dispensed in Spain or not.
DISCLAIMER: This article was written by a third-party contributor and does not reflect the opinion of Hemp.im, its management, staff, or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the company may believe that its expectations are based on reasonable assumptions, the actual results that the company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in Newsweed, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Hemp.im assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Hemp.im is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.